Gilead Sciences, Inc. (GILD) to Issue $0.57 Quarterly Dividend
Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Thursday, October 25th, RTT News reports. Investors of record on Friday, December 14th will be given a dividend of 0.57 per share by the biopharmaceutical company on Friday, December 28th. This represents a $2.28 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date is Thursday, December 13th.
Gilead Sciences has a dividend payout ratio of 34.8% meaning its dividend is sufficiently covered by earnings. Research analysts expect Gilead Sciences to earn $7.23 per share next year, which means the company should continue to be able to cover its $2.28 annual dividend with an expected future payout ratio of 31.5%.
NASDAQ:GILD opened at $68.15 on Friday. The company has a current ratio of 3.45, a quick ratio of 3.37 and a debt-to-equity ratio of 1.09. Gilead Sciences has a 52-week low of $64.27 and a 52-week high of $89.54. The stock has a market cap of $90.80 billion, a P/E ratio of 7.96, a PEG ratio of -2.72 and a beta of 1.01.
A number of equities analysts recently weighed in on the company. BidaskClub upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday. ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 1st. Oppenheimer reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, November 14th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, November 14th. Finally, Raymond James reiterated a “buy” rating on shares of Gilead Sciences in a research report on Thursday, November 1st. Eleven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $88.63.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $69.55, for a total transaction of $3,477,500.00. Following the completion of the sale, the director now directly owns 3,067,762 shares in the company, valued at approximately $213,362,847.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 150,000 shares of company stock valued at $10,939,500 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
See Also: Float
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.